Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Recruiting 8Active not recruiting 4Terminated 2Not yet recruiting 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Genitourinary 2Thoracic 1Breast 1

Conditions

Prostatic Neoplasms 2Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1

Interventions

Carboplatin 126Cisplatin 125Drug Therapy 104Bevacizumab 98Oxaliplatin 97Capecitabine 96Radiotherapy 94Gemcitabine 87Paclitaxel 85tislelizumab 84Cyclophosphamide 83Specimen Handling 80pembrolizumab 76toripalimab 67Magnetic Resonance Spectroscopy 63Injections 62Fluorouracil 62sintilimab 57anlotinib 53Surgical Procedures, Operative 50130-nm albumin-bound paclitaxel 50Docetaxel 49fludarabine 46Pemetrexed 45Standard of Care 43venetoclax 42Leucovorin 42Biopsy 42Irinotecan 41lenvatinib 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × Interventional × Glutamate Carboxypeptidase II × Clear all
NCT06982222 2026-05-13

Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones

National Cancer Institute (NCI)

Phase 1 Not yet recruiting
24 enrolled
BreastGenitourinaryThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Prostatic Neoplasms

NCT06129851 2023-11-13

Relugolix in Combination With Radiation Therapy for Treating Patients With High Risk Prostate Cancer

University of Kansas Medical Center

Phase 2 Not yet recruiting
90 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡